Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migrainesGeekWire • 09/03/21
FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock JumpsBenzinga • 09/03/21
Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of MigraineGlobeNewsWire • 09/03/21
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/17/21
Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/16/21
Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021GlobeNewsWire • 08/09/21
Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal HeadacheGlobeNewsWire • 08/09/21
Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare ConferenceGlobeNewsWire • 08/03/21
Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley BankGlobeNewsWire • 07/07/21
Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 06/07/21
Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and GutGlobeNewsWire • 05/18/21